Bio Serum Particles™ (BSPs) are proprietary, biologically derived components developed by BSP Biologics and are being studied for their potential to support cellular signaling and microenvironmental conditions within gynecologic and reproductive tissues.
BSPs are currently under investigation for their potential relevance in areas of women's health where tissue environment and cellular communication are important, including endometriosis, polycystic ovary syndrome (PCOS), age-related ovarian changes, and menopause-associated physiological shifts.
Preclinical and exploratory research is focused on understanding how BSPs may influence local biological signaling, tissue characteristics, and cellular interactions in reproductive and gynecologic settings.
BSPs are autologous biologic preparations processed under controlled conditions and intended for use within established regulatory frameworks governing human cellular and tissue-based products.
A research-focused view of ovarian aging, tissue signaling, and women's regenerative health
Menopause and perimenopause are not defined only by declining hormone levels. They also reflect broader changes in ovarian signaling, vascular support, inflammatory balance, and tissue-level communication across multiple biologic systems.
As a result, reproductive aging is increasingly understood as a systems-level biologic transition rather than a single hormonal event.
During hormonal transition, the ovarian and surrounding tissue environments undergo meaningful changes in how cells communicate, respond to signals, and maintain tissue function.
These changes may include:
Understanding these changes is important because ovarian aging may involve more than endocrine decline alone. It may also reflect changes in the biologic environment that supports tissue resilience, cellular coordination, and regenerative signaling.
BSP™ (Bio-Serum Particles) is a next-generation autologous biologic platform focused on the study of tissue communication and biologic signaling.
Rather than focusing on a single molecule or pathway, BSP™ is designed to explore coordinated signaling networks involving proteins, lipids, and regulatory nucleic acids within the body's own biologic environment.
This platform is being developed to help investigate how autologous particle-based signaling may relate to ovarian biology, endometrial response, tissue-level communication, and reproductive aging.
BSP™ is built around Bio-Serum Particles, a refined autologous signaling fraction intended to support a more focused biologic framework than broad blood-derived preparations.
This distinction allows BSP™ to be presented as:
Human tissues rely on dynamic communication systems that help regulate:
An important area of scientific interest is the role of extracellular vesicles and related biologic particles in intercellular communication.
These particles may carry:
This area of study is especially relevant in reproductive aging, where coordinated communication between ovarian, stromal, vascular, and endometrial tissues may influence how biologic transition is experienced over time.
Current areas of interest include:
BSP Biologics is committed to a structured, data-driven research model that may include:
This research-first approach is intended to support responsible scientific development, physician collaboration, and high-quality clinical observation.
Emerging research suggests that menopause and the menopausal transition involve more than changing estradiol levels alone. Published studies describe the transition as a broader biologic process associated with ovarian aging, altered cellular signaling, inflammatory and vascular changes, and measurable shifts in systemic biologic aging patterns.
Published literature has also highlighted the role of extracellular vesicles and related biologic particles as carriers of proteins, lipids, and regulatory nucleic acids involved in intercellular communication. These findings help support the broader scientific framework for studying tissue-level signaling and biologic communication in reproductive aging and women's health.
Patients interested in learning more about investigational research involving BSP™ during reproductive aging, perimenopause, or menopause are encouraged to speak with their physician.
Physicians, clinics, and research partners interested in scientific collaboration or future investigational programs may contact BSP Biologics for additional information.
Because Bio-Serum Particles are autologous—derived exclusively from each patient's own biologic sample—there is no risk of immunogenicity or immune rejection. Each therapy is uniquely tailored to the individual patient, maximizing compatibility and minimizing adverse reactions.
BSP Biologics operates in alignment with FDA 21 CFR Part 1271 frameworks governing human cellular and tissue-based products (HCT/Ps). All processes are conducted within controlled environments and aligned with internal standard operating procedures and applicable regulatory frameworks. Our commitment to safety, traceability, and clinical validation ensures that Women's Health practitioners can confidently integrate BSP therapeutics into their patient care protocols.
Each BSP preparation undergoes defined quality control assessments prior to clinical use, with release criteria designed to support consistency, traceability, and controlled handling of patient-derived biologic material.